Charles Schwab
ALT icon

Charles Schwab’s Altimmune ALT Stock Holding History

Charles Schwab’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
624,499
+272,818
+78% +$815K ﹤0.01% 2809
2026
Q1 		$1.08M Buy
351,681
+68,012
+24% +$289K ﹤0.01% 2884
2025
Q4 		$1.02M Buy
283,669
+79,220
+39% +$345K ﹤0.01% 2919
2025
Q3 		$771K Sell
204,449
-29,057
-12% -$112K ﹤0.01% 3035
2025
Q2 		$904K Buy
233,506
+21,627
+10% +$117K ﹤0.01% 2930
2025
Q1 		$1.06M Hold
211,879
– – ﹤0.01% 2817
2024
Q4 		$1.53M Buy
211,879
+253
+0.1% +$1.93K ﹤0.01% 2759
2024
Q3 		$1.3M Buy
211,626
+4,772
+2% +$32.3K ﹤0.01% 2834
2024
Q2 		$1.38M Buy
206,854
+64,149
+45% +$473K ﹤0.01% 2820
2024
Q1 		$1.45M Hold
142,705
– – ﹤0.01% 2685
2023
Q4 		$1.61M Buy
142,705
+9,310
+7% +$38.9K ﹤0.01% 2682
2023
Q3 		$347K Hold
133,395
– – ﹤0.01% 3185
2023
Q2 		$471K Buy
133,395
+112,999
+554% +$507K ﹤0.01% 3083
2023
Q1 		$86.1K Buy
20,396
+3,122
+18% +$37.1K ﹤0.01% 3273
2022
Q4 		$284K Hold
17,274
– – ﹤0.01% 3125
2022
Q3 		$221K Hold
17,274
– – ﹤0.01% 3151
2022
Q2 		$203K Sell
17,274
-86,948
-83% -$536K ﹤0.01% 3241
2022
Q1 		$635K Buy
104,222
+3,402
+3% +$25.1K ﹤0.01% 3031
2021
Q4 		$924K Buy
100,820
+2,565
+3% +$27.3K ﹤0.01% 2945
2021
Q3 		$1.11M Sell
98,255
-114,295
-54% -$1.39M ﹤0.01% 2835
2021
Q2 		$2.09M Buy
212,550
+76,056
+56% +$1.04M ﹤0.01% 2702
2021
Q1 		$1.93M Buy
136,494
+14,973
+12% +$242K ﹤0.01% 2678
2020
Q4 		$1.37M Buy
121,521
+2,724
+2% +$32.1K ﹤0.01% 2689
2020
Q3 		$1.57M Buy
+118,797
New +$2.37M ﹤0.01% 2576
2017
Q2 		– Sell
-331
Closed -$81K – 3103
2017
Q1 		$81K Hold
331
– – ﹤0.01% 3027
2016
Q4 		$324K Hold
331
– – ﹤0.01% 2819
2016
Q3 		$289K Hold
331
– – ﹤0.01% 2805
2016
Q2 		$243K Buy
+331
New +$226K ﹤0.01% 2867

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's ALT Position: Q2 2026 in Review

Charles Schwab increased its Altimmune (ALT) stake by 78% in Q2 2026, buying an estimated $815K and bringing the position to 624,499 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

Charles Schwab first reported a position in ALT in Q2 2016 and has held it in 28 quarters since. The position peaked at $2.09M in Q2 2021. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Charles Schwab held 624,499 shares of Altimmune worth $1.9M as of Q2 2026.
  • Charles Schwab bought 272,818 Altimmune shares in Q2 2026, an estimated $815K.
  • Altimmune made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2809 holding.
  • Charles Schwab first reported a position in Altimmune in Q2 2016 and has held it in 28 quarters since.
  • Charles Schwab's Altimmune position peaked at $2.09M in Q2 2021.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.